First Horizon National Corporation (NYSE:FHN) notched a -1.8% intraday decline moving at $15.27. When the opening bell rang, the price was $15.39. The number of shares that were traded during the day was 4386575, which corresponds to its 1-week volume average of 3138300 shares a day.

First Horizon National Corporation (FHN) Analyst Opinion

First Horizon National Corporation is currently rated as outperform by 19 stock analysts, with the company still having around 5.62% shares outstanding that can be sold short legally. The value of their shares went up by 6.12% last month. Over the course of a year, the stock has grown by 16.03%. Financial analysts are becoming more bullish than ever, with the 10 analysts who cover the activities of FHN advising investors to buy. Experts on Wall Street have set a price target of $17.12 for the stock. The decision was arrived after looking at their 12.12% gain from current levels. At the moment, First Horizon National Corporation (FHN) trading price is around -25.6% below its 52-week high.

First Horizon National Corporation Earnings Surprise

First Horizon National Corporation (FHN) was unsuccessful in overcoming the expected $0.36 as the stock recorded an earnings of $0.35 a piece during their last financial report presentation. Revenue, meanwhile, had a distance of 0.16% from the previous quarter, with the company recording $442.52 million in revenue.

First Horizon National Corporation (NYSE:FHN) Intraday View

The shares of First Horizon National Corporation (NYSE:FHN) have struggled and recovered 24.15% ever since it recorded its 52 week low. During the course of 5 days, the stock price volatility has remained at 1.54%, increasing the time frame to a month, the volatility recorded was 2.39%. The price of their shares has been successful in staying above its 20 days moving average, staying at a distance of 2.45% and while its 50 moving average is around 6.42%. A look at previous five trading session FHN stock had returned -0.39% and sank -9.77% when compared to its 200-day moving average that is $16.2. First Horizon National Corporation (FHN) will look to overcome its -19.88% fall that it witnessed in the past one year.

As the normal trading session ended, the stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA), fetched in a $0.02 spike to $6.47. The session began with the stock price at $6.41, hitting a high of $6.54 before down again. For the week, analysts seem to be okay with their neutral with the consensus call staying at 2.1. Akebia Therapeutics, Inc. gets 1 buy analyst recommendations while 2 recommend a hold and 0 rated it as a sell. The shares of the company tumbled -57.91% from its high $15.37, with their overall market value now roughly $742.82 million.

Akebia Therapeutics, Inc. (AKBA) Consensus Price Target

The mean recommendation of AKBA on Reuter’s scale remained unchanged from 2.12 to 2.12 within 30 days. This figure implies that the majority of analysts rate it as a hold. The price target for Akebia Therapeutics, Inc. (NASDAQ:AKBA) is now around $17.43 a share, implying the stock has what it takes to grow by 169.4%. The recent trading session also indicated the stock needs to add 363.68% more meet analysts’ high consensus price target.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Intraday Trading

The current trading volume of the company was 534305 shares during the last session. That compares with the recent average volume of 694860 shares. By the end of the regular trading session, the price volatility over a 1-week span was 4.76 % while over a month it stood at 5.64%. The stock price of AKBA dropped to $6.32 during the day and at a certain time in 12 months it traded as low as $5.2. It has made a 24.42% recovery since its 52-week low point and has returned 17% year-to-date.